2 2022 AT A GLANCE OUR PATIENTS OUR CLINICAL RESEARCH OUR BUSINESS Paxalisib has shown evidence of activity in multiple forms of brain cancer Kazia Therapeutics is a late clinical stage oncology company. We work alongside clinicians, researchers, and partners to bring impactful new therapies to patients with cancer. Kazia has grown rapidly, driven by progress in its world-class pipeline of cancer drug candidates 4 distinct indications in phase II studies with paxalisib 3 special designations awarded to paxalisib by FDA 400+ hospitals involved in paxalisib clinical trial program 6 scientific conference presentations of paxalisib data in 1H CY2022 82% of operating cashflows invested in R&D Indicative Analyst Valuation (US$) Mar 2022 Oct 2021 Apr 2021 Dec 2020 Jan 2020 $294M $277M $247M $174M $93M GLOBAL COLLABORATION for FY2022 Edison Research glioblastoma, DIPG, PCNSL, brain metastases Fast Track designation, Orphan Drug designation, Rare Pediatric Disease designation
RkJQdWJsaXNoZXIy MjE2NDg3